-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Downgrades Gilead Sciences to Market Perform, Lowers Price Target to $127

Benzinga·07/21/2026 16:42:34
Listen to the news
Leerink Partners analyst Daina Graybosch downgrades Gilead Sciences (NASDAQ:GILD) from Outperform to Market Perform and lowers the price target from $146 to $127.